Medidata Solutions, Inc. (MDSO) Stock Rating Reaffirmed by KeyCorp
Medidata Solutions, Inc. (NASDAQ:MDSO)‘s stock had its “buy” rating restated by investment analysts at KeyCorp in a report issued on Sunday. They currently have a $86.00 price objective on the stock. KeyCorp’s price target suggests a potential upside of 13.37% from the company’s current price.
A number of other analysts have also recently commented on the company. Jefferies Group LLC reaffirmed a “hold” rating and issued a $78.00 price target on shares of Medidata Solutions in a research note on Tuesday, August 22nd. BidaskClub cut Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Citigroup Inc. reaffirmed a “buy” rating and issued a $95.00 price target (up from $94.00) on shares of Medidata Solutions in a research note on Monday, July 24th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target (up from $75.00) on shares of Medidata Solutions in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Medidata Solutions currently has a consensus rating of “Buy” and an average target price of $84.00.
Medidata Solutions (MDSO) opened at 75.86 on Friday. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The firm has a market capitalization of $4.30 billion, a PE ratio of 122.55 and a beta of 1.81. The firm has a 50 day moving average of $74.69 and a 200 day moving average of $69.86.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $137.41 million during the quarter, compared to analysts’ expectations of $134.28 million. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. Medidata Solutions’s revenue was up 19.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.24 EPS. Equities analysts forecast that Medidata Solutions will post $1.28 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/17/medidata-solutions-inc-mdso-stock-rating-reaffirmed-by-keycorp.html.
In related news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wasatch Advisors Inc. increased its stake in Medidata Solutions by 3.9% during the 2nd quarter. Wasatch Advisors Inc. now owns 28,546 shares of the company’s stock worth $2,232,000 after purchasing an additional 1,083 shares in the last quarter. 1st Global Advisors Inc. increased its stake in Medidata Solutions by 0.5% during the 2nd quarter. 1st Global Advisors Inc. now owns 8,243 shares of the company’s stock worth $645,000 after purchasing an additional 37 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Medidata Solutions by 350.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 21,400 shares of the company’s stock worth $1,673,000 after purchasing an additional 16,651 shares in the last quarter. Bank of Nova Scotia increased its stake in Medidata Solutions by 7.7% during the 2nd quarter. Bank of Nova Scotia now owns 8,365 shares of the company’s stock worth $654,000 after purchasing an additional 600 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Medidata Solutions by 177.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 117,884 shares of the company’s stock worth $9,219,000 after purchasing an additional 75,443 shares in the last quarter. 97.53% of the stock is owned by institutional investors and hedge funds.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.